Niraparib
| CAS No. | 1038915-60-4 |
|---|---|
| MDL No. | MFCD17779309 |
| MF | C19H20N4O |
| MW | 320.40 |
| InChI Key | PCHKPVIQAHNQLW-CQSZACIVSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Niraparib is a 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide with S-configuration. It is a potent inhibitor of PARP1 and PARP2 (IC50: 3.8 nM and 2.1 nM, respectively) and is approved as a first-line maintenance treatment for women with advanced ovarian cancer following platinum-based chemotherapy. It functions as an antineoplastic agent, an EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor, a radiosensitizing agent, and an apoptosis inducer.
| CAS No. | 1038915-60-4 |
|---|---|
| Product Name | Niraparib |
Biological Targets
PARP2·PARP1
Associated Conditions
endometrial neoplasm·neoplasm·breast neoplasm·ovarian neoplasm·ovarian cancer·
* The information provided here is compiled from public sources and is for reference only.
